X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35) 35
humans (31) 31
hematology (27) 27
oncology (26) 26
middle aged (25) 25
male (24) 24
female (22) 22
rituximab (21) 21
adult (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
chemotherapy (19) 19
aged (18) 18
lymphomas (18) 18
prognosis (17) 17
survival (14) 14
therapy (13) 13
treatment outcome (12) 12
aged, 80 and over (11) 11
analysis (11) 11
cyclophosphamide (11) 11
neoplasm staging (11) 11
lymphoma (10) 10
cancer (9) 9
patients (9) 9
trial (8) 8
antineoplastic agents - therapeutic use (7) 7
immunochemotherapy (7) 7
mantle cell lymphoma (7) 7
multicenter (7) 7
retrospective studies (7) 7
chop (6) 6
disease progression (6) 6
follicular lymphoma (6) 6
hematology, oncology and palliative medicine (6) 6
maintenance (6) 6
non-hodgkins-lymphoma (6) 6
vincristine (6) 6
young adult (6) 6
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
care and treatment (5) 5
cyclophosphamide - administration & dosage (5) 5
cyclophosphamide - therapeutic use (5) 5
doxorubicin - administration & dosage (5) 5
lymphoma, follicular - drug therapy (5) 5
lymphoma, large b-cell, diffuse - drug therapy (5) 5
medical prognosis (5) 5
open-label (5) 5
prednisone (5) 5
prednisone - therapeutic use (5) 5
relapse (5) 5
remission induction (5) 5
rituximab - administration & dosage (5) 5
term-follow-up (5) 5
transplantation (5) 5
vincristine - administration & dosage (5) 5
vincristine - therapeutic use (5) 5
1st-line treatment (4) 4
antibodies, monoclonal, murine-derived - administration & dosage (4) 4
b-cell lymphoma (4) 4
cell survival (4) 4
chronic lymphocytic leukemia (4) 4
czech republic (4) 4
doxorubicin - therapeutic use (4) 4
hodgkin lymphoma (4) 4
medical research (4) 4
medicine (4) 4
medicine, experimental (4) 4
neoplasm recurrence, local - drug therapy (4) 4
plus rituximab (4) 4
prednisone - administration & dosage (4) 4
rituximab - therapeutic use (4) 4
safety (4) 4
stem-cell transplantation (4) 4
studies (4) 4
usage (4) 4
abridged index medicus (3) 3
adolescent (3) 3
aged patients (3) 3
antibodies, monoclonal, murine-derived (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
bone marrow (3) 3
brentuximab vedotin (3) 3
computed tomography (3) 3
cytarabine (3) 3
databases, factual (3) 3
disease (3) 3
doxorubicin (3) 3
efficacy (3) 3
elderly (3) 3
elderly patients (3) 3
elderly people (3) 3
elderly-patients (3) 3
etoposide - therapeutic use (3) 3
free survival (3) 3
geriatrics (3) 3
hematopoietic stem cell transplantation (3) 3
hemic and lymphatic diseases (3) 3
kaplan-meier estimate (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2014, Volume 9, Issue 7, p. e102594
Background: Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) have been documented as independent predictors of survival in patients with newly... 
TRIAL | SURVIVAL | SUBTYPE | MARKER | RITUXIMAB | MULTIDISCIPLINARY SCIENCES | PATIENTS OLDER | ABSOLUTE LYMPHOCYTE | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Age Factors | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Monocytes - pathology | Aged, 80 and over | Vincristine - administration & dosage | Female | Leukocyte Count | Retrospective Studies | Research Design - statistics & numerical data | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Factors | Biomarkers - analysis | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Large B-Cell, Diffuse - diagnosis | Lymphocytes - pathology | Survival Analysis | Aged | Antimitotic agents | Care and treatment | Lymphocytes | Analysis | Aged patients | Lymphomas | Antineoplastic agents | Elderly people | Multivariate analysis | Medical diagnosis | Risk factors | Age | Statistical analysis | Cell survival | Internal medicine | Risk groups | Hematology | Dentistry | Risk analysis | Patients | Survival | Lymphoma | Medicine | Studies | Population (statistical) | Chemotherapy | Monocytes | Hospitals | Lymphocytes B | Cell number | Medical prognosis | Predictions | Elderly | Cancer | Geriatrics | B-cell lymphoma
Journal Article
Onkologie (Czech Republic), ISSN 1802-4475, 2018, Volume 12, Issue 3, p. 95
Journal Article
by Horwitz, Steven and O'Connor, Owen A and O'Connor, Owen and Pro, Barbara and Illidge, Tim and Fanale, Michelle and Advani, Ranjana and Bartlett, Nancy and Bartlett, Nancy L and Christensen, Jacob Haaber and Morschhauser, Franck and Domingo-Domenech, Eva and Rossi, Giuseppe and Kim, Won Seog and Feldman, Tatyana and Lennard, Anne and Belada, David and Illés, Árpád and Tobinai, Kensei and Tsukasaki, Kunihiro and Yeh, Su-Peng and Shustov, Andrei and Hüttmann, Andreas and Savage, Kerry and Savage, Kerry J and Yuen, Sam and Iyer, Swaminathan and Zinzani, Pier Luigi and Hua, Zhaowei and Little, Meredith and Rao, Shangbang and Woolery, Joseph and Manley, Thomas and Trümper, Lorenz and Aboulafia, David and Alpdogan, Onder and Ando, Kiyoshi and Arcaini, Luca and Baldini, Luca and Bellam, Naresh and Yehuda, Dina Ben and Benedetti, Fabio and Borchman, Peter and Bordessoule, Dominique and Brice, Pauline and Briones, Javier and Caballero, Dolores and Carella, Angelo Michele and Chang, Hung and Cheong, June Weon and Cho, Seok-Goo and Choi, Ilseung and Choquet, Sylvain and Colita, Andrei and Congui, Angela Giovanna and D'amore, Francesco and Dang, Nam and Davison, Kelly and de Guibert, Sophie and Brown, Peter de Nully and Delwail, Vincent and Demeter, Judit and di Raimondo, Francesco and Do, Young Rok and Domingo, Eva and Douvas, Michael and Dreyling, Martin and Ernst, Thomas and Fay, Keith and Ferrero, Silvia Fernandez and Flinn, Ian Winchester and Forero-Torres, Andres and Fox, Christopher and Friedberg, Jonathan and Fukuhara, Noriko and Garcia-Marco, Jose and Cruz, Jorge Gayoso and Codina, Jose Gomez and Gressin, Remy and Grigg, Andrew and Gurion, Ronit and Haioun, Corinne and Hajek, Roman and Hanel, Mathias and Hatake, Kiyohiko and Hensen, Robert and Horowitz, Netanel and Huttmann, Andreas and Illes, Arpad and Ishizawa, Kenichi and Islas-Ohlmayer, Miguel and Jacobsen, Eric and Janakiram, Murali and Jurczak, Wojciech and Kaminski, Mark and Kato, Koji and Kirgner, Ilya and Kuo, Ching-Yuan and Lazaroiu, Mihaela Cornelia and Du, Katell Le and ... and ECHELON 2 Study Grp and ECHELON-2 Study Group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 229 - 240
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 319 - 331
Journal Article
by Trotman, Judith and Barrington, Sally F and Belada, David and Meignan, Michel and MacEwan, Robert and Owen, Carolyn and Ptáčník, Václav and Rosta, András and Fingerle-Rowson, Günter R and Zhu, Jiawen and Zhu, Jun and Nielsen, Tina and Sahin, Deniz and Hiddemann, Wolfgang and Marcus, Robert E and Davies, Andrew and Hertzberg, Mark and Grigg, Andrew and Cannell, Paul and Quach, Hang and Opat, Stephen and Tam, Constantine and Marlton, Paula and Janssens, Ann and Offner, Fritz and Van eygen, Koen and Sangha, Randeep and Mckay, Pam and Wilson, Jonathan and Van Der Jagt, Richard and Roitman, Daryl and Trneny, Marek and Mayer, Jiri and Le Du, Katell and Solal-Celigny, Philippe and Cartron, Guillaume and Foussard, Charles and Frickhofen, Norbert and Schmidt, Peter and Graeven, Ullrich and Gaska, Tobias and Schlag, Rudolf and Sökler, Martin and Prange-Krex, Gabriele and Florschütz, Axel and Lindemann, Hans-Walter and Schimmelpfennig, Christoph and Tonndorf, Solveig and Hänel, Mathias and Hess, Georg and Schalk, Enrico and Hütten, Heiko and Doelken, Gottfried and Pfreundschuh, Michael and Keller, Ulrich and Herold, Michael and Forstpointner, Roswitha and Vehling-Kaiser, Ursula and Hoffmann, Martin and Borbenyi, Zita and Udvardy, Miklos and Demeter, Judit and Rambaldi, Alessandro and Morra, Enrica and Massimo, Federico and Majolino, Ignazio and Balzarotti, Monica and Semenzato, Gianpietro and Canales Albendea, Miguel Angel and Peñalver Parraga, Francisco Javier and Soler Campos, Alfonso and Sancho Cia, Juan Manuel and Marquez Navarro, Jose Antonio and Grande Garcia, Carlos and Nilsson-Ehle, Herman and Mccarthy, Helen and Pocock, Chris and Sadullah, Shalal and Malladi, Ram and Radford, John and Kanfer, Ed and Kruger, Anton and Culligan, Dominic and Dyer, Martin and Pettengell, Ruth and Seymour, John and Gribben, John and Al-Ismail, Saad and Al-Refaie, Faris and Blesing, Norbert and Macnamara, Christopher and O'callaghan, Ann and Haynes, Andrew and Follows, George and Johnson, Roderick and Cunningham, David and Bowles, Kristian and Collins, Graham and Gallop-Evans, Eve and Robinson, Stephen and ... and PET investigators GALLIUM study and PET investigators from the GALLIUM study
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1530 - 1542
Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line... 
FDG-PET | CRITERIA | FONDAZIONE ITALIANA LINFOMI | SUBSET ANALYSIS | POSITRON-EMISSION-TOMOGRAPHY | INTERNATIONAL WORKSHOP | THERAPY | ONCOLOGY | PROGRESSION-FREE SURVIVAL | FOLL05 TRIAL | MINIMAL RESIDUAL DISEASE | Pets | Lymphomas | Prognosis | Analysis
Journal Article
Future Oncology, ISSN 1479-6694, 08/2016, Volume 12, Issue 15, pp. 1759 - 1768
We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and... 
DLBCL | gemcitabine | pixantrone | relapse | aggressive non-Hodgkin lymphoma | rituximab | DRUG | ADULT PATIENTS | MALIGNANT-LYMPHOMA | MULTICENTER PHASE-II | REGIMENS | TRIAL | SINGLE-AGENT | B-CELL LYMPHOMA | ONCOLOGY | CHOP
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2020, Volume 188, Issue 2, pp. 240 - 248
Summary PIX306 was a phase 3, randomised, single‐blind, multicentre trial conducted in adult patients with diffuse large B‐cell lymphoma (DLBCL) or follicular... 
DLBCL | gemcitabine | FL grade 3 | pixantrone | rituximab
Journal Article
Journal Article